The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

Scientists have built functional cancer-fighting immune cells directly inside living animals, skipping the expensive and time-consuming process of extracting a patient’s cells and engineering them in ...

Researchers developed lipid nanoparticles delivering an IDO-blocking drug, and mRNA to boost immune signaling. This dual action revives exhausted T cells, eliminates tumors in models, and may enable ...

CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of canc ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, have engineered a new ...

T cells are supposed to be relentless. These white blood cells patrol the body, identify threats, and destroy them.

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...